Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT04219475
Other study ID # OH-GBMHR
Secondary ID
Status Suspended
Phase
First received
Last updated
Start date January 2023
Est. completion date December 2025

Study information

Verified date April 2022
Source OncoHost Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

PROPHETIC GBM - Predicting response patterns to treatment in Glioblastoma (GBM) oncology patients based on host response evaluation during anti-cancer treatments


Description:

The goal of this research study is identify new host response proteins, pathways and mechanisms that are associated with responsiveness to GBM treatment modalities. This will serve as a tool for physicians when making treatment decisions. The investigators also aim to identify the metabolic pathways that could lead to better therapeutic options. The patients will be given their treatment according to the institute's standard of care. The patients will provide up to 5 blood samples and clinical data will be collected from their medical records. The data obtained from the blood samples and the medical records of the patients will be used to search for potential mechanisms that are involved in response to treatment, and to identify potential targets to increase the response, and hence, increase treatment effectiveness or suggest potential new treatments.


Recruitment information / eligibility

Status Suspended
Enrollment 1000
Est. completion date December 2025
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Provision of informed consent prior to any study-specific procedures. 2. Male or female aged at least 18 years. 3. KPS not less than 50. 4. Normal hematologic, renal and liver function: 1. Absolute neutrophil count above 1500/mm3, platelets above 100,000/mm3, hemoglobin above 9 g/dL; 2. Creatinine concentration not more than 1.4 mg/dL, or creatinine clearance above 40 mL/min; 3. Total bilirubin below 1.5 mg/dL, ALT+ AST levels not more than 3 times above the upper normal limit. 5. Patients planned to receive standard of care TMZ+RT treatment; TTF therapy during RT is permitted. Exclusion Criteria: 1. Any concurrent and/or other active malignancy that has required systemic treatment within 2 years of surgery. Except for basal cell carcinomas and squamous cell carcinomas that have been completely excised and considered cured at least 12 months prior to screening, and carcinoma in situ of the cervix that have been completely excised and cured at least 5 years prior to screening. 2. Participation in another clinical trial which includes an investigational drug. 3. Generalized impairment or mental incompetence that would render the patient unable to understand his/her participation in the study. 4. Pregnancy.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Israel Rambam medical center Haifa
Israel Rabin medical center Petah tikva
Israel Sourasky medical center Tel Aviv
Israel Sheba medical center Tel HaShomer

Sponsors (1)

Lead Sponsor Collaborator
OncoHost Ltd.

Country where clinical trial is conducted

Israel, 

References & Publications (3)

Shaked Y, Bocci G, Munoz R, Man S, Ebos JM, Hicklin DJ, Bertolini F, D'Amato R, Kerbel RS. Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose. Curr Cancer Drug Targets. 2005 Nov;5(7):551-9. Review. — View Citation

Shaked Y, Kerbel RS. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res. 2007 Aug 1;67(15):7055-8. Review. — View Citation

Shaked Y. Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects. Nat Rev Clin Oncol. 2016 Oct;13(10):611-26. doi: 10.1038/nrclinonc.2016.57. Epub 2016 Apr 26. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Response to treatment complete remission (CR); partial remission (PR), stable disease (SD), progressive disease (PD), suspected pseudo-progression, as defined by RANO One month after completion of TMZ + RT
Primary Response to treatment CR, PR, SD, PD, suspected pseudo-progression, as defined by RANO 3 months after treatment completion in the first year
Primary Response to treatment CR, PR, SD, PD, suspected pseudo-progression, as defined by RANO 6 months after treatment completion in the first year
Primary Response to treatment CR, PR, SD, PD, suspected pseudo-progression, as defined by RANO 9 months after treatment completion in the first year
Primary Response to treatment CR, PR, SD, PD, suspected pseudo-progression, as defined by RANO 12 months after treatment completion in the first year
Primary Response to treatment CR, PR, SD, PD, suspected pseudo-progression, as defined by RANO 18 months after treatment completion in the first year
Primary Response to treatment CR, PR, SD, PD, suspected pseudo-progression, as defined by RANO 24 months after treatment completion in the first year
Primary Response to treatment CR, PR, SD, PD, suspected pseudo-progression, as defined by RANO 30 months after treatment completion in the first year
Primary Response to treatment CR, PR, SD, PD, suspected pseudo-progression, as defined by RANO 36 months after treatment completion in the first year
Primary Blood levels of proteins Blood levels of proteins representing the Host response at baseline Pre-chemoradiation therapy - 7 days or less before the first administration
Primary Blood levels of proteins Changes in Blood levels of proteins representing the Host response compared to baseline After the first chemoradiation administration - at least 24 h after the first temozolomide (TMZ) dose, and between 24-48 h after the first radiation therapy (RT) dose
Primary Blood levels of proteins Changes in Blood levels of proteins representing the Host response compared to baseline 21+/-2 days after the first TMZ dose
Primary Blood levels of proteins Changes in Blood levels of proteins representing the Host response compared to baseline At first detection of progressive disease (PD) based on MRI evaluation during follow-up assessed up to 36 months
Primary Blood levels of proteins Changes in Blood levels of proteins representing the Host response compared to baseline If the previous detection of progression turned out to be pseudo-progression, then an additional blood sample should be drawn at time of progression, assessed up to 36 months
Secondary OS Overall survival Until death or 3 years
Secondary PFS Progression free survival up to 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT05664243 - A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT02768389 - Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma Early Phase 1
Recruiting NCT05635734 - Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT03679754 - Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 Phase 1
Completed NCT01250470 - Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma Phase 1
Terminated NCT03927222 - Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma Phase 2
Recruiting NCT03897491 - PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma Phase 2
Active, not recruiting NCT03587038 - OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma Phase 1
Completed NCT01922076 - Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Phase 1
Recruiting NCT04391062 - Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma Phase 2
Active, not recruiting NCT03661723 - Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma Phase 2
Active, not recruiting NCT02655601 - Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 Phase 2
Completed NCT02206230 - Trial of Hypofractionated Radiation Therapy for Glioblastoma Phase 2
Completed NCT03493932 - Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade Phase 1
Terminated NCT02709889 - Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06058988 - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Phase 2
Completed NCT03018288 - Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) Phase 2
Not yet recruiting NCT04552977 - A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma Phase 2
Withdrawn NCT03980249 - Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells Early Phase 1
Withdrawn NCT02876003 - Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma Phase 2